Senate Rx Patent Settlement Bill Revised To Limit Reporting Requirements
Executive Summary
The revised version of Sen. Patrick Leahy's (D-Vt.) patent settlement notification bill (S 754) would limit the types of generic-brand agreements that would need to be reported to antitrust agencies.
You may also be interested in...
Generic Drug Reforms: FTC Notification Bill Appears Ready To Move In 2003
A bill to require reporting of brand/generic patent settlements to the Federal Trade Commission appears ready to move early in the 108th Congress
Generic Drug Reforms: FTC Notification Bill Appears Ready To Move In 2003
A bill to require reporting of brand/generic patent settlements to the Federal Trade Commission appears ready to move early in the 108th Congress
Bush Generic Drug Reform Proposal Unlikely To End Push For Legislation
The White House Waxman/Hatch reform proposal is unlikely to end the push for legislative changes to the generic drug approval process